Insulet 10-Q 2026-09-30
PODD · CIK 1145197 · Form 10-Q · Period ended September 30, 2026 · Filed November 4, 2026
Revenue rose 19.2% to $842 million. Operating margin was 22.5%, against 16.7% a year earlier. Net income was $141 million.
8 sections, 133K characters. Original on sec.gov · ·
| Measure | Quarter ended Sep 30, 2026 | Quarter ended Sep 30, 2025 | Change |
|---|---|---|---|
| Revenue | $842M | $706M | +19.2% |
| Operating income | $190M | $118M | +61.3% |
| Net income | $141M | $87.6M | +61.1% |
| Diluted EPS | $2.03 | $1.24 | +63.7% |
| Operating margin* | 22.5% | 16.7% | +5.9 pts |
From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
OR
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission File Number 001-33462
INSULET CORPORATION
(Exact name of Registrant as specified in its charter)
| Delaware | 04-3523891 | ||||||||||||||||
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | ||||||||||||||||
| 100 Nagog Park | Acton | Massachusetts | 01720 | ||||||||||||||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (978) 600-7000
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☒ | Accelerated filer | ☐ | |||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common Stock, $0.001 Par Value Per Share | PODD | The NASDAQ Stock Market, LLC |
As of October 27, 2026, the registrant had 69,371,043 shares of common stock outstanding.
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
| Item 1. | Condensed Consolidated Financial Statements (Unaudited) |
INSULET CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| | | | | | | | | | | | | | | | | --- | --- | ---
Showing the first 8K of 81K characters. Open the full section
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes included in this quarterly report. The following discussion may contain forward-looking statements that reflect our plans, estimates and beliefs, which are subject to risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include those discussed under the headings “Risk Factors” and “Forward-Looking Statements” in both our Annual Report on Form 10-K for the year ended December 31, 2025 and in this quarterly report. Amounts have been calculated using actual, non-rounded figures; accordingly, amounts, percentages, and basis points may not recalculate, and columns and rows within tables may not add due to rounding.
Overview
Our mission is to transform the lives of people with diabetes. We develop, manufacture, and sell proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. Our Omnipod platform includes our latest-generation Omnipod 5 and its predecessor, Omnipod DASH, both of which eliminate the need for multiple daily injections using syringes or insulin pens and avoid the need for a traditional insulin pump and tubing. Omnipod DASH features a secure Bluetooth enabled Pod that is controlled through a smartphone-like Personal Diabetes Manager (“PDM”) with a color touch screen user interface. Omnipod 5, which builds on our Omnipod DASH mobile platform, is a tubeless automated insulin delivery (“AID”) system that integrates with a continuous glucose monitor (“CGM”) to automate insulin delivery and is fully controlled by a compatible personal smartphone or the Omnipod 5 Controller. It is indicated for people with type 1 diabetes and, in the United States, for adults with type 2 diabetes. The CGM is sold separately by third parties. The Omnipod 5 Pod integrates with Dexcom, Inc.’s G6 and G7 CGMs and with Abbott Diabetes Care, Inc.’s (“Abbott”) FreeStyle Libre 2 Plus sensor (“Libre 2 Plus”) in various markets. In June 2026, we expanded U.S. compatibility to include Abbott’s FreeStyle Libre 3 Plus sensor (“Libre 3 Plus”) and announced the U.S. rollout of Omnipod 5 algorithm enhancements, including a lower target glucose setting of 100 mg/dL. In addition, we recently expanded Omnipod 5 integration with Libre 3 Plus to 10 additional countries.
Our financial objective is to sustain profitable growth. To support this objective, we continue to expand the availability of Omnipod 5 in international markets. In February 2026, we launched Omnipod 5 and Omnipod Discover®, our web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers, in five countries in the Middle East, and in July 2026, we launched Omnipod 5 and Omnipod Discover in Spain. In addition, in October, we launched Omnipod Discover in the United States. We are also strengthening our international commercial organization and advancing regulatory, reimbursement, and market development initiatives to support future launches in additional markets.
In the United States, we sell our products through the pharmacy channel, which expands access and improves affordability by eliminating upfront costs. We also continue to increase awareness of Omnipod products through our direct-to-consumer advertising programs.
We continue to advance key product innovation initiatives, including expanding smartphone integration and CGM compatibility for Omnipod 5 and enhancing the customer experience through digital product and data capabilities. We are progressing the development of Omnipod 6, our next-generation AID system, and have completed enrollment for the type 1 diabetes cohort in our STRIVE 2 study. In addition, we continue to advance the development of our fully closed-loop AID system for people with type 2 diabetes, including completion of enrollment in the EVOLVE pivotal study, which is intended to support a planned 510(k) submission in 2027.
Finally, we continue to strengthen our global manufacturing capabilities, including investing in a new manufacturing plant in Costa Rica, to support our continued growth and future demand.
Results of Operations
Factors Affecting Operating Results
Our Pod is intended to be used continuously for up to three days, after which it may be replaced with a new disposable Pod. The unique patented design of the Omnipod allows us to provide Pod therapy at a relatively low or no up-front investment in regions where reimbursement allows for it. Our pay-as-you-go pricing model reduces the up-front financial risk for third-party payors. As we grow our customer base, we expect to generate an increasing portion of our revenues through sales of our disposable Pods, which provide a recurring revenue stream.
During the nine months ended September 30, 2026, we issued two voluntary medical device corrections (“the MDCs”), one in March and one in May, related to separate manufacturing issues that caused a tear in the cannula of certain Omnipod products. We recorded a net charge of $38.5 million associated with the MDCs during the nine months ended September 30, 2026. We estimate total costs associated with the MDCs will be approximately $50 million, most of which we expect to incur in 2026.
Revenue
| Three Months Ended September 30, | |||||||||||||||||||||||||||||
| (dollars in millions) | 2026 | 2025 | Percent Change | Currency Impact | Constant Currency**(1)** | ||||||||||||||||||||||||
| U.S. | $ | 570.4 | $ | 497.1 | 14.7 | % | — | % | 14.7 | % | |||||||||||||||||||
| International | 266.2 | 202.1 | 31.7 | % | (1.3) | % | 33.0 | % | |||||||||||||||||||||
| Total Omnipod Products | 836.6 | 699.2 | 19.7 | % | (0.4) | % | 20.0 | % | |||||||||||||||||||||
| Drug Delivery | 5.5 | 7.1 | (22.7) | % | — | % | (22.7) | % | |||||||||||||||||||||
| Total | $ | 842.0 | $ | 706.3 | 19.2 | % | (0.4) | % | 19.6 | % |
| Nine Months Ended September 30, | |||||||||||||||||||||||||||||
| (dollars in millions) | 2026 | 2025 | Percent Change | Currency Impact | Constant Currency**(1)** | ||||||||||||||||||||||||
| U.S. | $ | 1,630.1 | $ | 1,352.0 | 20.6 | % | — | % | 20.6 | % | |||||||||||||||||||
| International | 760.8 | 540.2 | 40.8 | % | 4.4 | % | 36.4 | % | |||||||||||||||||||||
| Total Omnipod Products | 2,390.9 | 1,892.2 | 26.4 | % | 1.3 | % | 25.1 | % | |||||||||||||||||||||
| Drug Delivery | 14.6 | 32.2 | (54.7) | % | — | % | (54.7) | % | |||||||||||||||||||||
| Total | $ | 2,405.4 | $ | 1,924.3 | 25.0 | % | 1.2 | % | 23.8 | % |
(1) Constant currency revenue growth is a non-GAAP financial measure and should be considered supplemental to, and not a substitute for, financial results prepared in accordance with GAAP. See “Non-GAAP Financial Measures.”
Total revenue for the three months ended September 30, 2026 increased $135.8 million, or 19.2%, to $842.0 million, compared with $706.3 million for the three months ended September 30, 2025. Total revenue for the nine months ended September 30, 2026 increased $481.1 million, or 25.0%, to $2.4 billion, compared with $1.9 billion for the nine months ended September 30, 2025. Constant currency revenue growth of 19.6% and 23.8% for the three and nine months ended September 30, 2026, respectively, was primarily driven by higher sales volume resulting from growth in our customer base.
U.S.
Revenue from the sale of Omnipod products in the U.S. increased $73.3 million, or 14.7%, to $570.4 million for the three months ended September 30, 2026, compared with $497.1 million for the three months ended September 30, 2025. Revenue from the sale of Omnipod products in the U.S. increased $278.1 million, or 20.6%, to $1,630.1 million for the nine months ended September 30, 2026, compared with $1,352.0 million for the nine months ended September 30, 2025. The increases in periods primarily resulted from higher sales volume due to growth in our customer base.
As discussed in Note 1 to our condensed consolidated financial statements, certain sales to one of our distributors were considered related party transactions during a portion of 2025. Revenue from the sale of Omnipod products in the U.S. included $184.5 million and $511.6 million of sales to this distributor for the three and nine months ended September 30, 2025, respectively.
International
Revenue from the sale of Omnipod products in our international markets increased $64.1 million, or 31.7%, to $266.2 million for the three months ended September 30, 2026, compared with $202.1 million for the three months ended September 30, 2025. Excluding the 1.3% unfavorable impact of foreign currency exchange rates, the remaining 33.0% increase in revenue was primarily due to higher volumes from our growing customer base and, to a lesser extent, higher average selling prices associated with the transition from Omnipod DASH to Omnipod 5.
Revenue from the sale of Omnipod products in our international markets increased $220.6 million, or 40.8%, to $760.8 million for the nine months ended September 30, 2026, compared with $540.2 million for the nine months ended September 30, 2025. Excluding the 4.4% favorable impact of foreign currency exchange rates, the remaining 36.4% increase in revenue was primarily due to higher volumes from our growing customer base and, to a lesser extent, higher average selling prices associated with the transition from Omnipod DASH to Omnipod 5.
Drug Delivery
Substantially all of our Drug Delivery revenue consists of sales of Pods to Amgen for use in the Neulasta® Onpro® kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy. Drug Delivery revenue was $5.5 million and $7.1 million for the three months ended September 30, 2026 and 2025, respectively, and $14.6 million and $32.2 million for the nine months ended September 30, 2026 and 2025, respectively. The $1.6 million and $17.6 million decreases for the three and nine months ended September 30, 2026, respectively, were driven by lower order volumes.
Costs and Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| (dollars in millions) | Amount | Percent of Revenue | Amount | Percent of Revenue | Amount | Percent of Revenue | Amount | Percent of Revenue | |||||||||||||||||||||||||||||||||||||||
| Cost of revenue | $ | 209.9 | 24.9 | % | $ | 196.2 | 27.8 | % | $ | 681.7 | 28.3 | % | $ | 553.0 | 28.7 | % | |||||||||||||||||||||||||||||||
| Research and development expenses | $ | 91.6 | 10.9 | % | $ | 77.2 | 10.9 | % | $ | 269.4 | 11.2 | % | $ | 210.2 | 10.9 | % | |||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | $ | 350.7 | 41.7 | % | $ | 315.2 | 44.6 | % | $ | 1,012.8 | 42.1 | % | $ | 833.6 | 43.3 | % |
Cost of Revenue
Cost of revenue for the three months ended September 30, 2026 increased $13.7 million, or 7.0%, to $209.9 million, compared with $196.2 million for the three months ended September 30, 2025. Gross margin was 75.1% for the three months ended September 30, 2026, compared with 72.2% for the three months ended September 30, 2025. The 280 basis point increase in gross margin was primarily driven by improved manufacturing efficiencies and, to a lesser extent, a 90 basis point benefit from an adjustment to our estimated warranty accrual associated with the voluntary MDCs, reflecting fewer Pod replacements than originally estimated.
Cost of revenue for the nine months ended September 30, 2026 increased $128.7 million, or 23.3%, to $681.7 million, compared with $553.0 million for the nine months ended September 30, 2025. Gross margin was 71.7% for the nine months ended September 30, 2026, compared with 71.3% for the nine months ended September 30, 2025. The 40 basis point increase in gross margin was primarily driven by improved manufacturing efficiencies, partially offset by higher warranty costs resulting from the voluntary MDCs discussed under “Factors Affecting Operating Results” and higher inventory excess and obsolescence reserves associated with the transition to our new Pod configurations.
We do not expect tariffs to have a significant impact on our gross margin in 2026; however, the elimination of the current exemption for certain medical devices would have a material impact on our gross margin and results of operations in future periods.
Research and Development Expenses
Research and development expenses for the three months ended September 30, 2026 increased $14.4 million, or 18.7%, to $91.6 million, compared with $77.2 million for the three months ended September 30, 2025. Research and development expenses for the nine months ended September 30, 2026 increased $59.2 million, or 28.2%, to $269.4 million, compared with $210.2 million for the nine months ended September 30, 2025. The increases in research and development expenses for both periods were primarily due to continued investment in our Omnipod and pipeline products, including Omnipod 6, our next-generation AID system, and a fully closed-loop AID system for type 2 diabetes, partially offset by a reduction in incentive compensation expense due to lower expected achievement of company performance targets in the current year.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended September 30, 2026 increased $35.5 million, or 11.3%, to $350.7 million, compared with $315.2 million for the three months ended September 30, 2025. Selling, general and administrative expenses for the nine months ended September 30, 2026 increased $179.2 million, or 21.5%, to $1,012.8 million, compared with $833.6 million for the nine months ended September 30, 2025. The increases for both periods were primarily attributable to higher personnel-related costs driven by increased headcount across our commercial, customer experience, regulatory, quality and other support functions, partially offset by a reduction in incentive compensation expense due to lower expected achievement of company performance targets in the current year. The increases also reflected higher spending on commercial support programs and consulting services. For the nine months ended September 30, 2026, the increase was further driven by higher depreciation and amortization expense associated with technology investments.
Non-Operating Items
Interest Expense and Income
Interest expense increased $0.5 million to $16.2 million for the three months ended September 30, 2026, compared with $15.6 million for the three months ended September 30, 2025, primarily due to fees associated with the refinancing of our Term Loan B in September 2026. For the nine months ended September 30, 2026, interest expense of $44.4 million was comparable to the prior-year period, as fees associated with the refinancing of our Term Loan B in September were comparable to the debt transaction costs incurred in the prior-year period associated with the issuance of senior unsecured notes and the repurchase of convertible notes.
Interest income decreased $4.5 million to $4.1 million for the three months ended September 30, 2026, compared with $8.6 million for the three months ended September 30, 2025. Interest income decreased $16.3 million to $12.6 million for the nine months ended September 30, 2026, compared with $29.0 million for the nine months ended September 30, 2025. The decreases for both periods were primarily due to lower average cash and investment balances.
We expect net interest expense for the full year 2026 to increase to approximately $40 million, primarily due to lower interest income.
Loss on Extinguishment of Debt
During both the three and nine months ended September 30, 2026, we recorded a $0.3 million loss on extinguishment of debt associated with the refinancing of our Term Loan B. During the nine months ended September 30, 2025, we repurchased all outstanding Convertible Notes ($796.0 million, net of issuance costs) for $1,052.2 million in cash, resulting in a $123.9 million loss on extinguishment of debt and a $132.3 million decrease in additional paid-in capital related to the portion of the Convertible Notes that was converted. Refer to Note 8 to our condensed consolidated financial statements for additional information.
Other income (expense), net
Other expense, net was $0.2 million and $0.7 million for the three and nine months ended September 30, 2026, respectively. Other income, net was $12.1 million and $11.2 million for the three and nine months ended September 30, 2025, respectively. Other income, net for both the three and nine months ended September 30, 2025 included a $12.5 million gain resulting from the change in fair value of the derivative asset associated with the redemption of our Convertible Senior Notes.
Income Tax Expense
Our effective tax rate was 20.4% and 20.0% for the three and nine months ended September 30, 2026, respectively, compared with 28.7% and 27.0% for the three and nine months ended September 30, 2025, respectively. The decreases in the effective tax rate in both periods were primarily due to the non-deductible loss on extinguishment of debt associated with the repurchase of our Convertible Senior Notes in the prior year and changes in the jurisdictional profit mix.
The Organization for Economic Co-operation and Development (“OECD”) and participating countries continue to advance the implementation of a 15% global minimum corporate tax (“Pillar Two”). Certain jurisdictions in which we operate, including the Netherlands and the United Kingdom, enacted legislation implementing aspects of Pillar Two during 2025. In January 2026, the OECD issued additional administrative guidance affecting the application of certain Pillar Two provisions to U.S.-parented multinational groups. We remain subject to Qualified Domestic Minimum Top-Up Taxes enacted by certain jurisdictions. Pillar Two did not have a material impact on our condensed consolidated financial statements for the three and nine months ended September 30, 2026; however, we continue to monitor developments and evaluate the potential impact on future periods.
During 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted in the United States. The OBBBA includes the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, changes to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. The legislation includes multiple effective dates for various provisions through 2027. Our effective tax rate for 2026 is affected by changes to the allocation of research and development expenses for purposes of the Foreign-Derived Deduction-Eligible Income (“FDDEI”) and other international tax reforms enacted under the OBBBA. The effects of the legislation were not material to our condensed consolidated financial statements for the three and nine months ended September 30, 2026.
Adjusted EBITDA**(1)**
The table below presents reconciliations of Adjusted EBITDA, a non-GAAP financial measure, to net income, the most directly comparable financial measure prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”):
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| (in millions) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net income | $ | 141.1 | $ | 87.6 | $ | 327.1 | $ | 145.5 | |||||||||||||||
| Interest expense, net | 12.1 | 7.0 | 31.7 | 15.5 | |||||||||||||||||||
| Income tax expense | 36.1 | 35.2 | 81.7 | 53.9 | |||||||||||||||||||
| Depreciation and amortization | 28.2 | 22.0 | 81.1 | 66.0 | |||||||||||||||||||
| Stock-based compensation expense(2) | 20.5 | 16.7 | 61.5 | 42.4 | |||||||||||||||||||
| Voluntary MDCs and related costs(3) | (4.5) | — | 32.2 | — | |||||||||||||||||||
| CFO and CEO transitions(4) | — | 4.0 | (0.5) | 9.4 | |||||||||||||||||||
| Loss on extinguishment of debt(5) | 0.3 | — | 0.3 | 123.9 | |||||||||||||||||||
| Gain on derivative asset(6) | — | (12.5) | — | (12.5) | |||||||||||||||||||
| Losses on investments(7) | — | — | — | 7.5 | |||||||||||||||||||
| Adjusted EBITDA | $ | 233.7 | $ | 160.0 | $ | 615.1 | $ | 451.5 |
(1) Adjusted EBITDA should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Non-GAAP Financial Measures.”
(2) Amounts for the three and nine months ended September 30, 2025 include $1.0 million and $11.7 million, respectively, related to the reversal of stock-based compensation expense associated with the departure of the Company’s former Chief Executive Officer (CEO).
(3) Represents estimated warranty and related costs associated with the voluntary MDCs. Refer to “Factors Affecting Operating Results” for additional information.
(4) The amount for the nine months ended September 30, 2026 represents an adjustment to severance benefits for the Company’s former Chief Financial Officer (CFO). The amounts for the three and nine months ended September 30, 2025 represent severance benefits for the Company’s former CEO and CFO.
(5) Amounts for the three and nine months ended September 30, 2026 relate to the refinancing of our Term Loan B. The amount for the nine months ended September 30, 2025 relates to the repurchase of Convertible Senior Notes.
(6) Represents the change in fair value of the derivative asset associated with the redemption of our Convertible Senior Notes.
(7) Represents losses associated with debt and equity investments.
Non-GAAP Financial Measures
Management uses the non-GAAP financial measures described below.
Constant currency revenue growth represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior-year period. We present constant currency revenue growth because we believe it provides meaningful information regarding our results on a consistent and comparable basis across periods. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with GAAP, to evaluate our operating results. It is also one of the performance metrics that determines management incentive compensation.
Adjusted EBITDA represents net income plus net interest expense (income), income tax expense (benefit), depreciation and amortization, stock-based compensation expense, and other significant transactions or events that affect the period-to-period comparability of our performance, as applicable. We present Adjusted EBITDA because management uses it as a supplemental measure to assess our performance, and we believe it is helpful to investors and other interested parties in comparing our performance from period to period.
Free cash flow is calculated as net cash provided by operating activities less capital expenditures. Management uses this non-GAAP measure, in addition to U.S. GAAP financial measures, to evaluate our operating results.
These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our financial results prepared in accordance with GAAP. In addition, the above definitions may differ from similarly titled measures used by others. Non-GAAP financial measures exclude the effect of items that increase or decrease our reported results of operations; accordingly, we strongly encourage investors to review our consolidated financial statements in their entirety.
Liquidity and Capital Resources
We believe that our current liquidity as further described below will be sufficient to meet our projected operating, investing and debt service requirements for at least the next twelve months.
Summary of Cash Flows
| Nine Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Cash provided by (used in): | |||||||||||
| Operating activities | $ | 325.7 | $ | 386.0 | |||||||
| Investing activities | (132.0) | (69.9) | |||||||||
| Financing activities | (321.9) | (522.8) | |||||||||
| Effect of exchange rate changes on cash and cash equivalents | (3.5) | 10.8 | |||||||||
| Net decrease in cash and cash equivalents | $ | (131.7) | $ | (195.9) |
Operating Activities
Net cash provided by operating activities of $325.7 million for the nine months ended September 30, 2026 was primarily attributable to net income, as adjusted for depreciation and amortization, stock-based compensation expense, and deferred income taxes, partially offset by a $177.3 million working capital outflow. The working capital outflow was primarily driven by a $179.6 million increase in accounts receivable and a $103.0 million increase in inventories, partially offset by a $72.0 million increase in accounts payable and a $40.1 million increase in accrued expenses and other liabilities. The increase in accounts receivable was primarily driven by the timing of distributor orders in the United States. The increase in inventories was primarily driven by a planned inventory build to satisfy anticipated demand and advance purchases of materials to mitigate supply risk and inflation. The increase in accounts payable was primarily due to the timing of payments. The increase in accrued expenses and other liabilities was driven by an increase in accrued rebates due to higher sales volume, partially offset by a decrease in accrued incentive compensation due to lower expected achievement of performance targets in the current year.
Investing Activities
Net cash used in investing activities was $132.0 million for the nine months ended September 30, 2026, compared with $69.9 million for the nine months ended September 30, 2025.
Capital Spending—Capital expenditures were $113.9 million for the nine months ended September 30, 2026, compared with $56.5 million for the nine months ended September 30, 2025. The $57.5 million increase primarily related to the purchase of machinery, equipment, and tooling for our existing manufacturing facilities and investments in our Costa Rica manufacturing plant. We expect capital expenditures for 2026 to increase compared with 2025 to support our continued global manufacturing expansion plans. We expect to fund our capital expenditures using existing cash and financing.
Investments in Developed Software—Investments in developed software were $13.1 million and $13.5 million for the nine months ended September 30, 2026 and 2025, respectively, and were primarily related to projects supporting our cloud-based capabilities.
Financing Activities
Net cash used in financing activities was $321.9 million for the nine months ended September 30, 2026, compared with $522.8 million for the nine months ended September 30, 2025.
Debt Issuance and Repayments—During the nine months ended September 30, 2026, we repaid $43.7 million of debt, primarily in connection with the refinancing of our Term Loan B, compared with payments of $33.4 million during the nine months ended September 30, 2025. During the nine months ended September 30, 2026 and 2025, we received proceeds of $30.0 million and $15.5 million, respectively, from the refinancing of our Term Loan B. In addition, during the nine months ended September 30, 2025, we received net proceeds of $440.7 million from the issuance of Senior Unsecured Notes and used those proceeds, together with $164.6 million of proceeds from the unwinding of the related capped call options, to partially fund the $1,052.2 million repurchase of Convertible Senior Notes.
Proceeds and Repayments from Secured Borrowing—During the nine months ended September 30, 2025, we received $49.4 million of cash advances from a third party to which we outsourced insurance claim submission activities in one of our international markets and repaid $46.8 million of such advances.
*Proceeds from Option Exercises—*Proceeds from option exercises were $0.7 million and $17.2 million for the nine months ended September 30, 2026 and 2025, respectively. The $16.5 million decrease was primarily driven by fewer option exercises due to our lower stock price.
*Payment of Taxes for Restricted Stock Net Settlements—*Payments for taxes related to net restricted and performance stock unit settlements were $16.9 million and $25.1 million for the nine months ended September 30, 2026 and 2025, respectively. The $8.2 million decrease was primarily driven by tax payments related to the vesting of performance and restricted stock units for a former executive in the prior year.
*Repurchase of Common Stock—*During the nine months ended September 30, 2026 and 2025, we repurchased common stock for an aggregate purchase price of $300.0 million and $59.6 million, respectively. Repurchases during the nine months ended September 30, 2026 were made pursuant to accelerated share repurchase agreements discussed under “Capitalization—Share Repurchase Program.”
Free Cash Flow
Free cash flow was $211.7 million for the nine months ended September 30, 2026, compared with $329.5 million for the nine months ended September 30, 2025. The $117.8 million decrease in free cash flow primarily resulted from higher cash used for working capital and higher capital expenditures, partially offset by an increase in operating income.
Free cash flow is a non-GAAP financial measure that should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. See “Non-GAAP Financial Measures.”
A reconciliation of net cash provided by operating activities (the most comparable U.S. GAAP measure) to free cash flow is as follows:
| Nine Months Ended September 30, | |||||||||||
| (in millions) | 2026 | 2025 | |||||||||
| Net cash provided by operating activities | $ | 325.7 | $ | 386.0 | |||||||
| Capital expenditures | (113.9) | (56.5) | |||||||||
| Free cash flow | $ | 211.7 | $ | 329.5 |
Capitalization
The following table contains several key measures to gauge our financial condition and liquidity at the end of each period:
| (in millions) | September 30, 2026 | December 31, 2025 | ||||||||||||
| Cash and cash equivalents | $ | 584.4 | $ | 716.1 | ||||||||||
| Current portion of long-term debt | $ | 19.1 | $ | 18.4 | ||||||||||
| Long-term debt, net | $ | 943.0 | $ | 930.8 | ||||||||||
| Total debt, net | $ | 962.2 | $ | 949.2 | ||||||||||
| Total stockholders’ equity | $ | 1,579.1 | $ | 1,515.2 | ||||||||||
| Debt-to-total capital ratio | 38 | % | 39 | % | ||||||||||
| Net debt-to-total capital ratio | 15 | % | 9 | % |
Credit Agreement
We have a $750 million senior secured revolving credit facility (the “Revolving Credit Facility”), which expires in 2030. At September 30, 2026, no amount was outstanding under the Revolving Credit Facility. The Revolving Credit Facility contains a covenant to maintain a specified leverage ratio when outstanding borrowings equal or exceed 35% of the aggregate commitments under the Revolving Credit Facility. It also contains other customary covenants, none of which are considered restrictive to our operations. Additionally, we have a Term Loan B, which matures in 2031, and contains covenants restricting or limiting our ability to incur additional indebtedness, make asset dispositions, create or permit liens, sell, transfer or exchange assets, guarantee certain indebtedness, and make acquisitions and other investments.
Senior Unsecured Notes
Our senior unsecured notes contain leverage and fixed charge coverage ratio covenants, each of which are measured upon the incurrence of future debt, as well as other customary covenants, none of which we consider restrictive to our operations.
Share Repurchase Program
In February 2026, the Board of Directors extended our $125 million share repurchase program to December 31, 2027 and authorized an additional $350 million of common stock repurchases under the program. Additionally, in February 2026, we entered into accelerated share repurchase agreements (“ASRs”) to repurchase $300 million of our common stock. The ASRs were completed by March 31, 2026. During the nine months ended September 30, 2026, we repurchased approximately 1.25 million shares of common stock. We had $115.4 million of remaining authorization under the share repurchase program as of September 30, 2026.
In October 2026, the Board of Directors authorized a $1 billion common stock repurchase program, effective through December 31, 2028. We expect to allocate approximately $400 million toward repurchases in 2026, funded with existing cash.
Commitments and Contingencies
Contractual Obligations
In 2026, we entered into a purchase agreement with NXP USA, Inc. pursuant to which we are committed to purchasing semi-conductor chips. As of September 30, 2026, our remaining purchase commitment under the agreement was approximately $45.1 million.
Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements in conformity with GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities.
Our accounting policies for pharmacy rebates and income taxes involve significant judgments and assumptions that are subject to inherent risks and uncertainties. There have been no significant changes in these critical accounting policies or the underlying assumptions and estimates from those disclosed in our annual consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.
Accounting Standards Issued and Not Yet Adopted
Information regarding accounting standards that have been issued but not yet adopted is included in Note 1 to our condensed consolidated financial statements.
FORWARD-LOOKING STATEMENTS
This quarterly report on Form 10-Q contains forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “would,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “risk” or “continue,” or the negative of these terms or other similar words or expressions. These statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, and financial condition.
The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties, and assumptions. These risks and uncertainties include, but are not limited to:
-
international regulatory, commercial and logistics risks, including any expansion of tariffs;
-
our dependence on a principal product platform;
-
the impact of competitive products, technological change, and product innovation;
-
our ability to maintain an effective sales force and expand our distribution network;
-
our ability to maintain and grow our customer base, including through expansion to additional international markets;
-
our ability to scale the business to support revenue growth;
-
our ability to secure and retain adequate coverage or reimbursement from third-party payors;
-
the impact of healthcare reform laws;
-
our ability to design, develop, manufacture, and commercialize future products;
-
unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of endorsements by diabetes associations or other organizations that are unfavorable;
-
our ability to protect our intellectual property and other proprietary rights;
-
potential conflicts with the intellectual property of third parties;
-
our inability to maintain existing or enter into new license or other agreements with respect to continuous glucose monitors, data management systems, or other rights necessary to sell our current products and/or commercialize future products;
-
worldwide macroeconomic and geopolitical uncertainty, including the war with Iran, as well as risks associated with any future pandemic, including supply chain disruptions;
-
the potential violation of anti-bribery/anti-corruption laws;
-
the concentration of manufacturing operations and storage of inventory in a limited number of locations;
-
the regulatory requirements and overall complexity in manufacturing our product and challenges associated with starting new manufacturing lines;
-
supply disruptions or price fluctuations involving sole-source or third-party suppliers on which we are dependent;
-
failure to retain key suppliers;
-
challenges to the future development of our non-insulin drug delivery product line;
-
our failure, or the failure of our contract manufacturer or component suppliers, to comply with the U.S. Food and Drug Administration’s quality system regulations, our or our contract manufacturer's ability to successfully implement quality inspection systems, or other manufacturing difficulties;
-
extensive government regulation applicable to medical devices, as well as complex and evolving privacy, data protection and artificial intelligence laws;
-
adverse regulatory or legal actions relating to current or future Omnipod products;
-
potential adverse impacts resulting from a recall, or discovery of product safety issues, including potential adverse impacts relating to our recent medical device corrections;
-
breaches or failures of our product or information technology systems, including by cyberattack;
-
our ability to maintain the privacy and security of Company and third-party information;
-
our ability to attract, motivate, and retain key personnel;
-
risks associated with potential future acquisitions or investments in new businesses;
-
our ability to raise additional funds on acceptable terms or at all;
-
restrictions imposed by our Credit Agreement; and
-
changes in tax laws or exposure to significant tax liabilities.
The risk factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in this Quarterly Report could cause our results to differ materially from those expressed in forward-looking statements. In addition, there may be other risks and uncertainties that we are unable to predict at this time or that we currently do not expect to have a material adverse effect on our business. Actual results could differ materially from those projected in the forward-looking statements; accordingly, you should not rely on forward-looking statements as predictions of future events. We expressly disclaim any obligation to update these forward-looking statements other than as required by law.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There were no material changes to our quantitative and qualitative disclosures about market risk during the nine months ended September 30, 2026. See “Part II. Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of our interest rate and foreign currency exchange risks.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 (“the Exchange Act”), as amended, is recorded, processed, summarized, and reported within the specified time periods, and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based on this evaluation, our chief executive officer (principal executive officer) and chief financial officer (principal financial officer) concluded that, as of that date, our disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Information regarding our material pending legal proceedings, if any, is included in Note 11 to our condensed consolidated financial statements in this Form 10-Q and is incorporated herein by reference.
Item 1A. Risk Factors
See “Risks Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 for a discussion of risks to which our business, financial condition, results of operations, and cash flows are subject. There have been no material changes to the risk factors disclosed in that Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Rule 10b5-1 Plans
During the third quarter of 2026, no director or executive officer of the Company adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K.
Item 6. Exhibits
| Number | Description | |||||||
| 10.1*+ | Amendment No. 9, dated as of August 25, 2026, to the Amended and Restated Development and Commercialization Agreement by and between Insulet Corporation and Abbott Diabetes Care Inc. dated as of September 13, 2021. | |||||||
| 10.2# | Insulet Nonqualified Deferred Compensation Plan (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed September 16, 2026). | |||||||
| 10.3 | Ninth Amendment to Credit Agreement, dated September 21, 2026, among Insulet Corporation, Insulet MA Securities Corporation, Morgan Stanley Senior Funding, Inc., as administrative agent, and the other lenders party thereto (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K, filed September 21, 2026). | |||||||
| 31.1* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Executive Officer. | |||||||
| 31.2* | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 by Chief Financial Officer. | |||||||
| 32.1** | Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer and Chief Financial Officer. | |||||||
| 101 | The following materials from Insulet Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 formatted in iXBRL (Inline eXtensible Business Reporting Language), as follows: | |||||||
| (i) Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2026 and December 31, 2025 | ||||||||
| (ii) Condensed Consolidated Statements of Income (Unaudited) for the three and nine months ended September 30, 2026 and 2025 | ||||||||
| (iii) Condensed Consolidated Statements of Comprehensive Income (Unaudited) for the three and nine months ended September 30, 2026 and 2025 | ||||||||
| (iv) Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) for the three and nine months ended September 30, 2026 and 2025 | ||||||||
| (v) Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2026 and 2025 | ||||||||
| (vi) Condensed Notes (Unaudited) to Consolidated Financial Statements | ||||||||
| * | Filed herewith. | |||||||
| ** | Furnished herewith. | |||||||
| + | Certain portions of this exhibit are considered confidential and have been omitted as permitted under SEC rules and regulations. | |||||||
| # | Management contract or compensation plan. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INSULET CORPORATION (Registrant) | ||||||||
| Date: | November 4, 2026 | /s/ Ashley A. McEvoy | ||||||
| Ashley A. McEvoy | ||||||||
| Chief Executive Officer (Principal Executive Officer) |
| Date: | November 4, 2026 | /s/ Flavia H. Pease | ||||||
| Flavia H. Pease | ||||||||
| Chief Financial Officer, Executive Vice President (Principal Financial Officer) |